Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Sanofi ADR (NASDAQ: SNY) closed at $57.79 down -1.38% from its previous closing price of $58.60. In other words, the price has decreased by -$1.38 from its previous closing price. On the day, 2.0 million shares were traded. SNY stock price reached its highest trading level at $58.155 during the session, while it also had its lowest trading level at $57.18.
Ratios:
For a deeper understanding of Sanofi ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 18.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.79. For the most recent quarter (mrq), Quick Ratio is recorded 0.73 and its Current Ratio is at 1.08. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.17.
On July 26, 2024, Argus reiterated its Buy rating and also lowered its target price recommendation from $55 to $60.
On January 23, 2024, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $55.Morgan Stanley initiated its Equal-Weight rating on January 23, 2024, with a $55 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNY now has a Market Capitalization of 148045840384 and an Enterprise Value of 83152060416. As of this moment, Sanofi’s Price-to-Earnings (P/E) ratio for their current fiscal year is 24.14, and their Forward P/E ratio for the next fiscal year is 11.80. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.97. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.18 while its Price-to-Book (P/B) ratio in mrq is 1.81. Its current Enterprise Value per Revenue stands at 1.878 whereas that against EBITDA is 7.129.
Stock Price History:
The Beta on a monthly basis for SNY is 0.53, which has changed by 0.20220506 over the last 52 weeks, in comparison to a change of 0.08190584 over the same period for the S&P500. Over the past 52 weeks, SNY has reached a high of $60.12, while it has fallen to a 52-week low of $45.22. The 50-Day Moving Average of the stock is 6.50%, while the 200-Day Moving Average is calculated to be 10.22%.
Shares Statistics:
For the past three months, SNY has traded an average of 2.55M shares per day and 2918870 over the past ten days. A total of 2.61B shares are outstanding, with a floating share count of 2.45B. Insiders hold about 0.00% of the company’s shares, while institutions hold 10.81% stake in the company. Shares short for SNY as of 1740700800 were 5416836 with a Short Ratio of 2.12, compared to 1738281600 on 4882048. Therefore, it implies a Short% of Shares Outstanding of 5416836 and a Short% of Float of 0.23999999000000002.
Dividends & Splits
According to the company, the forward annual dividend rate for SNY is 2.04, from 3.92 in the trailing year. Against a Trailing Annual Dividend Yield of 0.0668942The stock’s 5-year Average Dividend Yield is 3.72.
Earnings Estimates
The stock of Sanofi ADR (SNY) is currently drawing attention from 1.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.87, with high estimates of $0.87 and low estimates of $0.87.
Analysts are recommending an EPS of between $4.75 and $4.38 for the fiscal current year, implying an average EPS of $4.51. EPS for the following year is $4.98, with 3.0 analysts recommending between $5.2 and $4.77.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $9.69B this quarter.It ranges from a high estimate of $9.79B to a low estimate of $9.6B. As of the current estimate, Sanofi ADR’s year-ago sales were $10.46BFor the next quarter, 5 analysts are estimating revenue of $10.13B. There is a high estimate of $10.35B for the next quarter, whereas the lowest estimate is $9.84B.
A total of 14 analysts have provided revenue estimates for SNY’s current fiscal year. The highest revenue estimate was $52.34B, while the lowest revenue estimate was $44B, resulting in an average revenue estimate of $46.14B. In the same quarter a year ago, actual revenue was $41.08BBased on 17 analysts’ estimates, the company’s revenue will be $50.35B in the next fiscal year. The high estimate is $57.06B and the low estimate is $46.62B.
